pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Sword Health proposes acquisition of mental-health startup Headspace, linking two digital health unicorns

Aug 25, 2026·read at Endpoints ↗DealNeutral

Sword Health announced a proposal to acquire Headspace, a mental-health startup, according to a filing with Massachusetts state officials.

The deal would combine two digital-health companies that have each achieved unicorn status, potentially expanding the range of mental-health services offered by Sword Health.

The proposal was disclosed in a state document, and the companies have not yet confirmed final terms or a closing timeline.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Sword Health plans to buy Headspace, filing says”

read at Endpoints ↗
86 words · retrieved 56m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Psychiatry & CNS2

related stories

  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27What’s the true risk for eating disorders with GLP-1s?STAT
  • Apr 27STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialSTAT
  • Apr 27STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studySTAT
  • Apr 27STAT+: Veradermics’ hair loss drug succeeds in late-stage trialSTAT